BR112022016743A2 - Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos - Google Patents
Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmosInfo
- Publication number
- BR112022016743A2 BR112022016743A2 BR112022016743A BR112022016743A BR112022016743A2 BR 112022016743 A2 BR112022016743 A2 BR 112022016743A2 BR 112022016743 A BR112022016743 A BR 112022016743A BR 112022016743 A BR112022016743 A BR 112022016743A BR 112022016743 A2 BR112022016743 A2 BR 112022016743A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- histone deacetylase
- inhibitor
- derivative compounds
- oxadiazole derivative
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- -1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS Chemical class 0.000 title abstract 2
- 229940122617 Histone deacetylase 6 inhibitor Drugs 0.000 title abstract 2
- 102000011427 Histone Deacetylase 6 Human genes 0.000 abstract 4
- 108010023925 Histone Deacetylase 6 Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
COMPOSTOS DE DERIVADO DE 1,3,4-OXADIAZOL COMO INIBIDOR DE HISTONA DESACETILASE 6 E A COMPOSIÇÃO FARMACÊUTICA QUE COMPREENDE OS MESMOS. A presente invenção se refere a um composto inovador que tem uma atividade inibitória de histona desacetilase 6 (HDAC6), um isômero do mesmo ou um sal farmaceuticamente aceitável do mesmo, o uso do mesmo para preparar um medicamento terapêutico; uma composição farmacêutica que contém o mesmo e um método de tratamento usando a composição; e um método de preparação da mesma. O composto inovador, o isômero do mesmo ou sal farmaceuticamente aceitável do mesmo de acordo com a presente invenção tem a atividade inibitória de HDAC6, que é eficaz na prevenção ou tratamento de doenças mediadas por HDAC6, incluindo câncer, doenças inflamatórias, doenças autoimunes, neurológicas ou doenças neurodegenerativas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200023249A KR102537616B1 (ko) | 2020-02-25 | 2020-02-25 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PCT/KR2021/002362 WO2021172886A1 (en) | 2020-02-25 | 2021-02-25 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016743A2 true BR112022016743A2 (pt) | 2022-10-18 |
Family
ID=77490107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016743A BR112022016743A2 (pt) | 2020-02-25 | 2021-02-25 | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230147859A1 (pt) |
| EP (1) | EP4110780B1 (pt) |
| JP (1) | JP7525662B2 (pt) |
| KR (1) | KR102537616B1 (pt) |
| CN (1) | CN115151542A (pt) |
| AU (1) | AU2021225683B2 (pt) |
| BR (1) | BR112022016743A2 (pt) |
| CA (1) | CA3167361A1 (pt) |
| MX (1) | MX2022010394A (pt) |
| TW (1) | TWI786553B (pt) |
| WO (1) | WO2021172886A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| KR102537615B1 (ko) * | 2020-02-25 | 2023-05-30 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR064491A1 (es) * | 2006-12-22 | 2009-04-08 | Astex Therapeutics Ltd | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. |
| JP2010531875A (ja) * | 2007-06-26 | 2010-09-30 | ギリード・サイエンシズ・インコーポレーテッド | イミダゾピリジニルチアゾリルヒストンデアセチラーゼ阻害剤 |
| TWI482771B (zh) | 2009-05-04 | 2015-05-01 | Du Pont | 磺醯胺殺線蟲劑 |
| JP2013515677A (ja) | 2009-09-23 | 2013-05-09 | アミラ ファーマシューティカルズ，インク． | ５−リポキシゲナーゼのインドリジンインヒビター |
| DK2526093T3 (en) | 2010-01-22 | 2016-11-14 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as proteindeacetylasehæmmere and methods of use thereof |
| JP6233812B2 (ja) | 2012-03-07 | 2017-11-22 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 選択的ヒストンデアセチラーゼ６阻害剤 |
| MY194018A (en) * | 2015-07-27 | 2022-11-08 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2017030938A1 (en) * | 2015-08-14 | 2017-02-23 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017222950A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| KR102537615B1 (ko) * | 2020-02-25 | 2023-05-30 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
-
2020
- 2020-02-25 KR KR1020200023249A patent/KR102537616B1/ko active IP Right Grant
-
2021
- 2021-02-25 JP JP2022576784A patent/JP7525662B2/ja active Active
- 2021-02-25 AU AU2021225683A patent/AU2021225683B2/en active Active
- 2021-02-25 MX MX2022010394A patent/MX2022010394A/es unknown
- 2021-02-25 US US17/904,806 patent/US20230147859A1/en active Pending
- 2021-02-25 EP EP21760387.7A patent/EP4110780B1/en active Active
- 2021-02-25 TW TW110106772A patent/TWI786553B/zh active
- 2021-02-25 CN CN202180016680.4A patent/CN115151542A/zh active Pending
- 2021-02-25 CA CA3167361A patent/CA3167361A1/en active Pending
- 2021-02-25 WO PCT/KR2021/002362 patent/WO2021172886A1/en active Application Filing
- 2021-02-25 BR BR112022016743A patent/BR112022016743A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021225683A1 (en) | 2022-09-01 |
| TWI786553B (zh) | 2022-12-11 |
| JP2023516824A (ja) | 2023-04-20 |
| CN115151542A (zh) | 2022-10-04 |
| JP7525662B2 (ja) | 2024-07-30 |
| KR20210108274A (ko) | 2021-09-02 |
| WO2021172886A1 (en) | 2021-09-02 |
| KR102537616B1 (ko) | 2023-05-26 |
| EP4110780A4 (en) | 2023-07-05 |
| TW202146408A (zh) | 2021-12-16 |
| EP4110780B1 (en) | 2024-08-07 |
| EP4110780A1 (en) | 2023-01-04 |
| CA3167361A1 (en) | 2021-09-02 |
| MX2022010394A (es) | 2022-09-07 |
| US20230147859A1 (en) | 2023-05-11 |
| AU2021225683B2 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11065227B2 (en) | Use of cannabinoids in the treatment of multiple myeloma | |
| BR112023024551A2 (pt) | Análogos de triazolo-pirimidina para tratamento de doenças relacionadas à inibição de recq helicase de síndrome de werner (wrn) | |
| BR112022016761A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112022016743A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| NZ739026A (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| BR112018002304A8 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112017027798A2 (pt) | compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
| PH12016501735B1 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
| SV2010003491A (es) | 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| Nguyen et al. | Sigma receptors as potential therapeutic targets for neuroprotection | |
| BR112023000560A2 (pt) | Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos | |
| BR112021023770A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112022025946A2 (pt) | Composto, composição farmacêutica e método de tratamento de uma doença | |
| BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
| BR112021026170A2 (pt) | Composição farmacêutica para tratamento de tumor?? | |
| BR112022020731A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| BR112023025251A2 (pt) | Composto ou sal, éster, solvato, pró-fármaco, derivado marcado com isótopo ou isômero farmaceuticamente aceitável deste, composição, composição farmacêutica e método para tratamento de uma doença ou distúrbio inibindo a transdução de sinal mediada por tyk2 | |
| BR112023020805A2 (pt) | Compostos de 1,3,4-oxadiazol tiocarbonil como inibidor de histona desacetilase 6 e composição farmacêutica compreendendo estes | |
| BR112022005729A2 (pt) | Compostos de pirazolopiridina como inibidores seletivos da quinase de btk | |
| BR112021019779A2 (pt) | Novo composto e composição para prevenção ou tratamento de doenças respiratórias compreendendo os mesmos como ingrediente ativo | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |